{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:52:33Z","timestamp":1791381153692,"version":"4.3.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":107,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) of antiepileptic drugs (AEDs) is essential for optimizing seizure control while minimizing toxicity, particularly in resource-constrained settings. Palestine\u2019s West Bank healthcare system operates under profound geopolitical and infrastructural constraints. This study presents the first large-scale, multi-decade retrospective analysis of AED TDM patterns from a Palestinian multi-branch laboratory network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using 9,232 individual AED serum level measurements from 5,197 unique patients recorded in the Laboratory Information System of Medicare Laboratories (33 branches, West Bank) from 2001 to 2026. Six AEDs were evaluated: carbamazepine, levetiracetam, lamotrigine, phenobarbital, phenytoin, and valproic acid. Results were classified as sub-therapeutic, therapeutic, or toxic against established reference ranges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 9,232 measurements, 53.4% were therapeutic, 40.4% sub-therapeutic, and 6.1% toxic. Phenytoin showed the worst therapeutic control (31.0% therapeutic; median 8.4 mcg\/mL). Valproic acid exhibited a 47.8% sub-therapeutic rate despite the highest test volume (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094,021). Lamotrigine had the highest toxic proportion (25.9%). Levetiracetam demonstrated the best control (88.6% therapeutic). Testing volume increased approximately 5.7-fold over the 25-year period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Frequent out-of-range AED levels, particularly for phenytoin and valproic acid, reflect complex pharmacokinetic and systemic challenges in the West Bank. The overall sub-therapeutic rate (40.4%) highlights the urgent need for enhanced TDM programs, improved patient adherence strategies, and strengthened pharmaceutical care infrastructure in this conflict-affected region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-026-05103-0","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:42:05Z","timestamp":1782099725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic drug monitoring of antiepileptic drugs in the West Bank, Palestine: a 25-year retrospective cohort study from a multi-branch laboratory network"],"prefix":"10.1186","volume":"26","author":[{"given":"Ibrahim","family":"Salhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Karmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"5103_CR1","unstructured":"World Health Organization. Epilepsy: a public health imperative. Geneva: WHO. 2019. Available from: https:\/\/www.who.int\/publications\/i\/item\/epilepsy-a-public-health-imperative."},{"issue":"3","key":"5103_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","volume":"88","author":"KM Fiest","year":"2017","unstructured":"Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296\u2013303. https:\/\/doi.org\/10.1212\/WNL.0000000000003509.","journal-title":"Neurology"},{"issue":"2","key":"5103_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000503831","volume":"54","author":"E Beghi","year":"2020","unstructured":"Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54(2):185\u201391. https:\/\/doi.org\/10.1159\/000503831.","journal-title":"Neuroepidemiology"},{"key":"5103_CR4","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1136\/bmj.e345","volume":"344","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ, Kwan P. Newer drugs for focal epilepsy in adults. BMJ. 2012;344:e345. https:\/\/doi.org\/10.1136\/bmj.e345.","journal-title":"BMJ"},{"issue":"7","key":"5103_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs \u2014 best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Comm Therapeutic Strategies Epilepsia. 2008;49(7):1239\u201376. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x.","journal-title":"ILAE Comm Therapeutic Strategies Epilepsia"},{"issue":"4","key":"5103_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/17425255.2020.1724956","volume":"16","author":"CJ Landmark","year":"2020","unstructured":"Landmark CJ, Johannessen SI, Patsalos PN. Therapeutic drug monitoring of antiepileptic drugs: current status and recommendations. Expert Opin Drug Metab Toxicol. 2020;16(4):329\u201343. https:\/\/doi.org\/10.1080\/17425255.2020.1724956.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"5103_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","volume":"43","author":"PN Patsalos","year":"2002","unstructured":"Patsalos PN, Fr\u00f6scher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43(4):365\u201385. https:\/\/doi.org\/10.1046\/j.1528-1157.2002.13001.x.","journal-title":"Epilepsia"},{"issue":"6","key":"5103_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6):347\u201356. https:\/\/doi.org\/10.1016\/S1474-4422(03)00409-5.","journal-title":"Lancet Neurol"},{"key":"5103_CR9","volume-title":"Applied Clinical Pharmacokinetics","author":"LA Bauer","year":"2014","unstructured":"Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed. New York: McGraw-Hill Education; 2014.","edition":"3"},{"key":"5103_CR10","volume-title":"Basic Clinical Pharmacokinetics","author":"ME Winter","year":"2010","unstructured":"Winter ME. Basic Clinical Pharmacokinetics. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.","edition":"5"},{"issue":"10","key":"5103_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10):695\u2013714. https:\/\/doi.org\/10.2165\/00023210-200216100-00004.","journal-title":"CNS Drugs"},{"issue":"2","key":"5103_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1046\/j.1528-1157.2003.25302.x","volume":"44","author":"R Coupez","year":"2003","unstructured":"Coupez R, Nicolas JM, Browne TR. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia. 2003;44(2):171\u20138. https:\/\/doi.org\/10.1046\/j.1528-1157.2003.25302.x.","journal-title":"Epilepsia"},{"key":"5103_CR13","first-page":"1","volume":"13","author":"PN Patsalos","year":"2004","unstructured":"Patsalos PN. Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Rev Contemp Pharmacother. 2004;13:1\u2013168.","journal-title":"Rev Contemp Pharmacother"},{"issue":"9666","key":"5103_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(09)60107-0","volume":"373","author":"R Giacaman","year":"2009","unstructured":"Giacaman R, Khatib R, Shabaneh L, et al. Health status and health services in the occupied Palestinian territory. Lancet. 2009;373(9666):837\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(09)60107-0.","journal-title":"Lancet"},{"key":"5103_CR15","unstructured":"Palestinian Ministry of Health. Health Status in Palestine: Annual Report 2022. Ramallah: Palestinian Authority Ministry of Health; 2023."},{"key":"5103_CR16","volume-title":"West Bank and Gaza Health Sector Review","author":"World Bank","year":"2021","unstructured":"World Bank. West Bank and Gaza Health Sector Review. Washington DC: World Bank Group; 2021."},{"key":"5103_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12882-016-0317-4","volume":"17","author":"R Al-Ramahi","year":"2016","unstructured":"Al-Ramahi R, Raddad AR, Rashed AO, Bsharat A, Abu-Ghazaleh D, Yasin E, Shehab O. Evaluation of potential drug-drug interactions among Palestinian hemodialysis patients. BMC Nephrol. 2016;17:96. https:\/\/doi.org\/10.1186\/s12882-016-0317-4.","journal-title":"BMC Nephrol"},{"key":"5103_CR18","volume-title":"Essentials of Clinical Epilepsy","author":"A Guberman","year":"1999","unstructured":"Guberman A, Bruni J. Essentials of Clinical Epilepsy. 2nd ed. Boston: Butterworth-Heinemann; 1999.","edition":"2"},{"issue":"10","key":"5103_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.addr.2012.01.014","volume":"64","author":"GD Anderson","year":"2012","unstructured":"Anderson GD, Saneto RP. Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev. 2012;64(10):911\u20138. https:\/\/doi.org\/10.1016\/j.addr.2012.01.014.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"5103_CR20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit. 2018;40(5):526\u201348. https:\/\/doi.org\/10.1097\/FTD.0000000000000546.","journal-title":"Ther Drug Monit"},{"key":"5103_CR21","first-page":"71","volume-title":"Clinical Pharmacology: Basic Principles in Therapeutics","author":"LB Sheiner","year":"1978","unstructured":"Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morrelli HF, editors. Clinical Pharmacology: Basic Principles in Therapeutics. 2nd ed. New York: Macmillan; 1978. pp. 71\u2013109.","edition":"2"},{"issue":"2","key":"5103_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1742-7843.2006.pto_309.x","volume":"99","author":"M Joerger","year":"2006","unstructured":"Joerger M, Huitema ADR, Boogerd W, van der Sande JJM, Schellens JHM, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol. 2006;99(2):133\u201340. https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_309.x.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"5103_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/00148581-200608020-00004","volume":"8","author":"R Guerrini","year":"2006","unstructured":"Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs. 2006;8(2):113\u201329. https:\/\/doi.org\/10.2165\/00148581-200608020-00004.","journal-title":"Paediatr Drugs"},{"issue":"3","key":"5103_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/157015910792246254","volume":"8","author":"SI Johannessen","year":"2010","unstructured":"Johannessen SI, Landmark CJ. Antiepileptic drug interactions \u2014 principles and clinical implications. Curr Neuropharmacol. 2010;8(3):254\u201367. https:\/\/doi.org\/10.2174\/157015910792246254.","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"5103_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15(2):210\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(15)00314-2.","journal-title":"Lancet Neurol"},{"issue":"1","key":"5103_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/ern.09.136","volume":"10","author":"C Johannessen Landmark","year":"2010","unstructured":"Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother. 2010;10(1):119\u201340. https:\/\/doi.org\/10.1586\/ern.09.136.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"5103_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1528-1157.2000.tb00144.x","volume":"41","author":"G Jannuzzi","year":"2000","unstructured":"Jannuzzi G, Cian P, Fattore C, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia. 2000;41(2):222\u201330. https:\/\/doi.org\/10.1111\/j.1528-1157.2000.tb00144.x.","journal-title":"Epilepsia"},{"issue":"2","key":"5103_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/FTD.0b013e318167d11b","volume":"30","author":"GD Anderson","year":"2008","unstructured":"Anderson GD. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit. 2008;30(2):173\u201380. https:\/\/doi.org\/10.1097\/FTD.0b013e318167d11b.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"5103_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","volume":"12","author":"AM Kanner","year":"2016","unstructured":"Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol. 2016;12(2):106\u201316. https:\/\/doi.org\/10.1038\/nrneurol.2015.243.","journal-title":"Nat Rev Neurol"},{"issue":"Suppl 9","key":"5103_CR30","first-page":"S20","volume":"40","author":"SC Schachter","year":"1999","unstructured":"Schachter SC. Antiepileptic drug therapy: general treatment principles and application for special patient populations. Epilepsia. 1999;40(Suppl 9):S20\u20135.","journal-title":"Epilepsia"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05103-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:01:55Z","timestamp":1791378115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05103-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5103"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05103-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9722279\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study used de-identified data from the Medicare Laboratories LIS. Ethical approval was obtained from Medicare labs IRB (ML-2026-01-3 -LIS). Patient informed consent was waived by the IRB in accordance with the retrospective and de-identified nature of the data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"630"}}